DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cataract 12 multiple types — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCataract 12 multiple types maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cataract 12 multiple types is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Cataract is the most common cause of blindness worldwide, and congenital cataracts are both phenotypically and genotypically heterogeneous. As of 2020, 115 genes had been found associated with syndromic and non-syndromic cataract, and 38 disease-causing genes had been identified for isolated cataract alone. A 1996 review of over 150 patients with autosomal dominant cataract proposed a clinical classification of eight phenotypes: anterior polar, posterior polar, nuclear, cortical, blue-dot, lamellar, coralliform, and pulverulent. A 1997 study of 560 subjects using the Oxford Clinical Cataract Classification and Grading System found that two nuclear features (white nuclear scatter and brunescence) were closely related, as were coronary flakes and focal-dots, but these two groupings were negatively associated. Cortical spoke, fibrefolds, and waterclefts were all associated with one another and positively associated with coronary flakes and focal-dots. Posterior subcapsular and anterior subcapsular opacity were associated with one another and with cortical spokes.
A 2023 retrospective study of 520 acquired cataract patients (mean age 67.57, 55% female) found that mixed cataract (44%) and nuclear sclerotic cataract (32%) were the most common types. Posterior subcapsular cataract prevalence was significantly higher in females than males (16.1% vs. 7.3%, p = 0.002), while men had more nuclear sclerotic cataracts than females (38% vs. 27.3%, p = 0.009). Patients with posterior subcapsular cataract were significantly younger than those with other types (all p-values < 0.001). The study found that cataract types were independent of ABO blood group and Rh type (P > 0.05).
No drug treatment for cataract is mentioned in any of these abstracts. The 2020 review notes that future avenues include cellular therapies and pharmacological treatments, but provides no data on any such intervention. What is still missing is any completed or even proposed clinical trial of a drug for cataract reversal or prevention, any validated molecular target for pharmacological treatment in humans, and any patient stratification beyond the descriptive phenotype and blood-group associations reported here.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Ophthalmology · 2020 · 85 citations · open access
AbstractCataract is the most common cause of blindness in the world; during infancy and early childhood, it frequently results in visual impairment. Congenital cataracts are phenotypically and genotypically heterogeneous and can occur in isolation or in association with other systemic disorders. Significant progress has been made in identifying the molecular genetic basis of cataract; 115 genes to date have been found to be associated with syndromic and non-syndromic cataract and 38 disease-causing genes have been identified to date to be associated with isolated cataract. In this review, we briefly discuss lens development and cataractogenesis, detail the variable cataract phenotypes and molecular mechanisms, including genotype-phenotype correlations, and explore future novel therapeutic avenues including cellular therapies and pharmacological treatments.
The clinical and genetic heterogeneity of autosomal dominant cataract
AbstractABSTRACT As part of a linkage study we have reviewed over 150 patients with autosomal dominant cataract and suggest a clinical classification of the different phenotypes consisting of anterior and posterior polar, nuclear, cortical, blue‐dot, lamellar, coralliform and pulverulent cataracts.
Associations between lens features assessed in the Oxford Clinical Cataract Classification and Grading System
AbstractPURPOSE: To study the associations between eleven lens features graded according to the Oxford Clinical Cataract Classification and Grading System (OCCCGS). METHOD: 560 subjects taking part in the Melton Eye Study had their lenses graded according to the OCCCGS by one of two examiners. Associations between features were examined using log-linear models for categorised grades. Adjustment was made for age, sex and grader. RESULTS: Within subjects, the two nuclear features, white nuclear scatter and brunescence, are closely related with one another, as are coronary flakes and focal-dots, but these two groupings are negatively associated. Cortical spoke, fibrefolds and waterclefts are all associated with one another and this group is positively associated with coronary flakes and focal-dots. Posterior subcapsular and anterior subcapsular opacity are associated with one another and with cortical spokes. A within-eye analysis gives similar results. CONCLUSION: These associations may be important in defining cataract subtypes and in identifying minor features that indicate early cataract development.
BMC Research Notes · 2023 · 1 citations · open access
Evaluation of the frequency of ABO and Rh-Hr blood-group systems in different acquired cataracts type
AbstractOBJECTIVES: This study evaluated the relationship between acquired cataract's different types and the ABO and Rh blood classes. METHODS: Overall, 520 patients, by randomized sampling method, participated in this retrospective cross-sectional study. After reviewing the patient's medical records and laboratory results, the patient's demographics, ABO group, Rh, and cataract type were documented. RESULTS: A total of 520 patients were included in the research, with a mean age of 67.57 ± 11.85. Most of them were female (n = 286, 55%). Mix (n = 230, 44%) and nuclear sclerotic (NS) (n = 167, 32%) cataracts were the most common types. The posterior subcapsular cataract (PSC) prevalence in females was significantly higher than in males (16.1% vs.7.3% p = 0.002). Also, men had more NS cataracts than females (89, 38% vs. 78, 27.3%) (p = 0.009). Patients with PSC were significantly younger than others (all p-values < 0.001). Our results showed that cataract types are independent of blood group types and Rh (P > 0.05). CONCLUSION: Although our findings showed that cataract types are independent of blood group types and Rh, they can be compared with future studies on the association of other Blood-Group Systems in developing acquired cataracts.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
